Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer McKesson Corporation by Year
McKesson Corporation — Share of consolidated total revenues (%) (%)
Pfizer McKesson Corporation: 25.0% in FY2025, up 2.0 pts from a year earlier. That is the highest of the 9 years on record here.
Latest, FY2025
25.0%
Period ended Dec 31, 2025
Change on a year earlier
+2.0 pts
23.0% in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Note 17 — Significant Customers & Geographic Concentration.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | McKesson Corporation — Share of consolidated total revenues (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.0% | +2.0 pts | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 23.0% | +7.0 pts | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 16.0% | +8.0 pts | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 8.0% | -1.0 pts | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 9.0% | -7.0 pts | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 16.0% | +1.0 pts | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 15.0% | +2.0 pts | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 13.0% | -3.0 pts | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 16.0% | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer McKesson Corporation (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/conc-mckesson
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.